ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
129.922,38
0,69%
S&P 500
6.021,63
0,57%
US Dollar vs BRL
5,8128
0,03%
Bitcoin
93.248,70
1,39%
Brent Oil
72,355
-0,13%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Legend Biotech Corporation (LEGN)

  7. Legend Biotech Corporation (LEGN) Notícias

LEGN

Legend Biotech (LEGN)

Legend Biotech Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LEGN
DataHoraFonteTítuloCódigoCompanhia
14/11/202410:46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LEGNLegend Biotech Corporation
12/11/202409:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
12/11/202409:00GlobeNewswire Inc.Legend Biotech Reports Third Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
07/11/202409:30GlobeNewswire Inc.Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:LEGNLegend Biotech Corporation
05/11/202411:10GlobeNewswire Inc.Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
04/11/202409:30GlobeNewswire Inc.Legend Biotech Appoints Alan Bash as President of CARVYKTI®NASDAQ:LEGNLegend Biotech Corporation
24/10/202409:00GlobeNewswire Inc.Legend Biotech to Host Investor Conference Call on Third Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
03/10/202408:30GlobeNewswire Inc.Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in PhiladelphiaNASDAQ:LEGNLegend Biotech Corporation
27/09/202417:35GlobeNewswire Inc.CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second LineNASDAQ:LEGNLegend Biotech Corporation
25/09/202416:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
20/08/202409:00GlobeNewswire Inc.Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
09/08/202408:00GlobeNewswire Inc.Legend Biotech Reports Second Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
09/08/202406:50IH Market NewsUS Futures Climb Following Thursday’s Rally, Oil Prices SteadyNASDAQ:LEGNLegend Biotech Corporation
08/08/202417:05GlobeNewswire Inc.Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of DirectorsNASDAQ:LEGNLegend Biotech Corporation
26/07/202408:00GlobeNewswire Inc.Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024NASDAQ:LEGNLegend Biotech Corporation
10/07/202409:00GlobeNewswire Inc.Legend Biotech to Host Investor Conference Call on Second Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
02/07/202409:00GlobeNewswire Inc.Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
03/06/202417:00Business WireLegend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
29/05/202409:00Business WireLegend Biotech to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
23/05/202418:00Business WireLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
13/05/202408:10IH Market NewsU.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed ReactionsNASDAQ:LEGNLegend Biotech Corporation
13/05/202408:00Business WireLegend Biotech Reports First Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
22/04/202414:05Business WireCARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/04/202409:00Business WireLegend Biotech to Host Investor Conference Call on First Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
06/04/202400:30Business WireLegend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
19/03/202409:30Business WireLegend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) ReportNASDAQ:LEGNLegend Biotech Corporation
15/03/202416:15Business WireCARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/03/202408:00Business WireLegend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
11/03/202407:39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:LEGNLegend Biotech Corporation
28/02/202420:46Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LEGNLegend Biotech Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:LEGN

Seu Histórico Recente

BIT
P1U0Z4
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Economize até 60%* para TRADER PLUS

1 ano 40%, 2 anos 50% e *3 anos 60%

*Ao longo de 3 anos $ 1475.65 apenas $ 590.25